The #WeekinOncology by OncoAlert🚨 This week, Dr. @Erman_Akkus 🇹🇷takes us through two important phase 3 trials advancing the treatment landscape in hepatocellular carcinoma (HCC) out in the Lancet and Lancet Gastroenterology and hepatology 📌 TALENTACE On-demand TACE + atezolizumab and bevacizumab vs on-demand TACE alone In patients with untreated, unresectable HCC and intermediate-to-high tumour burden, adding atezolizumab + bevacizumab to on-demand TACE significantly improved TACE progression-free survival: ➡️ 11.3 vs 7.0 months ➡️ HR 0.71 (95% CI 0.55–0.92; p=0.0089) Overall survival remains immature, with follow-up ongoing. 📌 TALENTOP Liver resection after atezolizumab + bevacizumab vs maintenance therapy For patients with advanced HCC and macrovascular invasion who responded to induction atezolizumab + bevacizumab and were considered resectable, liver resection significantly prolonged time to treatment failure: ➡️ 20.4 vs 11.8 months ➡️ HR 0.60 (95% CI 0.39–0.91; p=0.015) Together, these studies highlight an evolving treatment paradigm in HCC—bringing locoregional therapy, systemic therapy, and surgery into increasingly integrated treatment strategies. 🎥 Don’t miss Dr. Erman Akkus breaking down what these results could mean for clinical practice. @CathyEngMD @BenWestphalen @graokane @NiuSanford @AndresC27622123 @GillSharlene @pashtoonkasi @DrVilmaPBarcia @Erman_Akkus @GIMedOnc @UOzkerim @MarioBalsaMD @p_ciracimd @DraMartinezLago @DaisukeKotani @Aiims1742 @ARosen380 @realbowtiedoc @KoheiShitara @MarioBalsaMD @GaiaGriguolo @scocmem